Eli Lilly reported positive top‑line Phase III results for retatrutide, a GIP/GLP‑1/glucagon triple‑agonist, showing clinically meaningful reductions in A1C and large weight loss in adults with type 2 diabetes. In the Transcend‑T2D‑1 trial, the highest doses produced up to a 1.9 percentage‑point HbA1c drop and substantial percentage weight loss over 40 weeks, with safety consistent with incretin‑class agents. The dataset positions retatrutide as a potentially differentiated option for patients with diabetes who also need aggressive weight management and could shape competitive dynamics among next‑generation metabolic drugs.